
NASDAQHealthcareMedical - Specialties
أحدث البيانات المتاحة
19.58 US$
+0.35 US$ · +1.82%
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
الإغلاق السابق
19.58 US$
+0.35 US$ · +1.82%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
نطاق اليوم
السعر الحالي 19.58 US$
نطاق 52 أسبوعًا
السعر الحالي 19.58 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
48
قيمة عادلة
المشاعر
66
صعودي
المخاطر
26
مخاطر متوسطة
الزخم
57
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
نطاق اليوم
السعر الحالي 19.58 US$
نطاق 52 أسبوعًا
السعر الحالي 19.58 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 112.82 مليون USD | 119.91 مليون USD | 120.79 مليون USD | 113.83 مليون USD | 147.79 مليون USD |
| تكلفة البضاعة المباعة | 49.01 مليون USD | 43.91 مليون USD | 38.26 مليون USD | 40.61 مليون USD | 64.85 مليون USD |
| الربح الإجمالي | 63.81 مليون USD | 76 مليون USD | 82.53 مليون USD | 73.22 مليون USD | 82.94 مليون USD |
| البحث والتطوير | 25.77 مليون USD | 25.54 مليون USD | 21.76 مليون USD | 18.32 مليون USD | 27.33 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 49.09 مليون USD | 55.56 مليون USD | 59.93 مليون USD | 51.23 مليون USD | 74.1 مليون USD |
| نفقات التشغيل | 74.86 مليون USD | 81.1 مليون USD | 81.69 مليون USD | 69.55 مليون USD | 80.33 مليون USD |
| دخل الفوائد | — | — | 2.31 مليون USD | 654 ألف USD | — |
| الاستهلاك والإطفاء | 5.73 مليون USD | 8.12 مليون USD | 14.22 مليون USD | 14.49 مليون USD | 14.32 مليون USD |
| الدخل التشغيلي | −11.05 مليون USD | −5.1 مليون USD | 844 ألف USD | 3.67 مليون USD | 2.62 مليون USD |
| صافي الدخل | −10.88 مليون USD | −56.39 مليون USD | −82.67 مليون USD | −14.86 مليون USD | 4.13 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
21.00 US$
ارتفاع محتمل بنسبة 7.25%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI8.3 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM5.88 مليون0.01%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF3.26 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2.93 مليون0.01%26.81 مليار USD0.33%37.95 US$-0.39%
Fidelity Small-Mid Multifactor ETFFSMD2.06 مليون0.08%2.49 مليار USD0.15%49.96 US$+0.48%
Dimensional - US Small Cap ETFDFAS1.97 مليون0.01%33.87 مليار USD0.31%78.35 US$+0.32%
Vanguard Russell 2000 ETFVTWO1.38 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
Schwab U.S. Small-Cap ETFSCHA1.33 مليون0.01%21.82 مليار USD0.03%32.79 US$+0.40%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Fidelity Small-Mid Multifactor ETFFSMD
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.